Making the compound Amanitin available for cancer therapies
Our mission is to research and develop drugs for cancer patients to provide them
with a targeted, tailor-made and highly effective treatment option
ADC Drug Development
We use the active ingredient Amanitin from the death cap mushroom for cancer therapies by researching, producing and clinically developing so-called Antibody Amanitin Conjugates.
ATACs belong to the class of Antibody Drug Conjugates (ADCs), which combine the high affinity and specificity of antibodies with the efficacy of small toxic molecules to fight cancer.
PR: Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101
PR: Heidelberg Pharma’s Partner Takeda Reached Development Milestone
PR: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business
AH: Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics